2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.61K
Market Cap
€1.99M
Enterprise Value€39.03M
Total Cash (Recent Filing)€7.63M
Total Debt (Recent Filing)€8.91M
Price to Earnings (P/E)―
Beta-85.49
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding1,426,541,500
10 Day Avg. Volume2,610
30 Day Avg. Volume2,610
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-1.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageLow leverage limits direct balance-sheet pressure from debt and preserves financial flexibility relative to a highly indebted medtech business. This can help SpectraCure allocate future capital toward clinical development and commercialization without a large existing debt burden.
Targeted PDT PlatformSpectraCure’s platform is designed to target tumor ablation while monitoring treatment in real time, creating a differentiated clinical proposition within minimally invasive cancer care. If validated and adopted, this integrated approach could support durable relevance in hospital settings.
Recurring Procedure Revenue PotentialCombining capital equipment with procedure-related consumables could create a revenue model that extends beyond one-time system installations. Each installed system may support repeat treatment activity, giving successful clinical adoption the potential to build a more durable revenue base.
Bears Say
Minimal Revenue BaseThe absence of reported revenue alongside substantial operating losses shows that the business has not yet demonstrated commercial traction. This leaves future performance highly dependent on converting clinical development into approvals, adoption, and paying treatment activity.
Persistent Cash BurnSustained negative operating and free cash flow means current operations are not self-funding. Unless commercialization improves materially, SpectraCure may need external funding or existing cash reserves to support development, increasing financial dependence over the next several quarters.
Shrinking Equity BaseThe declining equity base indicates that persistent losses are consuming shareholder capital despite modest leverage. Deeply negative returns reduce the company’s ability to compound internally generated value and increase the importance of achieving profitability before resources are depleted.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was <€0.01 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €1.99M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is Nov 13, 2026 which is in 20 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on Aug 21, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 1,426,541,500 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.
Technical Analysis
Paxman AB
―
SciBase Holding AB
―
Bactiguard Holding AB
―
BrainCool AB
―
ScandiDos AB
―